Author

W. J. Chng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2

Frequent Co-Authors

H. Yang· 2 shared O. An· 2 shared B. A. Ahidjo· 1 shared B. C. Han· 1 shared B. Wang· 1 shared B. Wong Jern Han· 1 shared C. K. Mok· 1 shared C. Lin· 1 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Yang

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Aberrant non-canonical NF-kappaB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma

D. A. Ang, J.-M. Carter, K. Deka, J. H. L. TAN, J. Zhou, Q. Chen, W. J. Chng, N. Harmston, Y. Li

This study shows that aberrant non-canonical NF-kappaB signalling reprograms the epigenome to drive oncogenic transcriptomes in multiple myeloma by promoting super-enhancers and cis-regulatory interactions.

bioRxiv · Jan 9, 2024Cancer Biology

ADAR2-repressed RNA editing: a novel mechanism contributing to t (8:21) AML leukemogenesis

M. Guo, T. H. M. Chan, O. An, Y. Song, Z. H. Tan, V. H. E. Ng, X. Cao, W. J. Chng, M. Osato, H. Yang, Q. Zhou, L. Chen, D. G. Tenen

This study identifies ADAR2 downregulation in t(8;21) AML and shows its role in suppressing leukemogenesis through RNA editing.

bioRxiv · Oct 18, 2021 · PreprintCancer Biology

The oncogenic E3 ligase TRIP12 suppresses epithelial-mesenchymal transition (EMT) and metastasis-related processes through ZEB1/2

K. K. Lee, D. Rajagopalan, S. S. Bhatia, W. J. Chng, S. Jha

This study shows TRIP12 suppresses EMT and metastasis by inhibiting ZEB1/2 in breast cancer, based on patient data and cell experiments.

bioRxiv · Nov 4, 2020Cancer Biology

Calcitriol, the active form of vitamin D, is a promising candidate for COVID-19 prophylaxis

C. K. Mok, Y. L. Ng, B. A. Ahidjo, R. C. H. Lee, M. W. C. Loe, J. Liu, K. S. Tan, P. Kaur, W. J. Chng, J. E. L. Wong, D. Y. Wang, E. W. Hao, X. Hao, Y. W. Tan, T. M. Mak, , J. J. H. Chu

This study identifies calcitriol, the active form of vitamin D, as a potent inhibitor of SARS-CoV-2, suggesting its potential as a prophylactic agent against COVID-19.

bioRxiv · Jun 21, 2020 · PreprintMicrobiology

Three-dimensional Genome Organization Maps in Normal Haematopoietic Stem Cells and Acute Myeloid Leukemia

B. Wang, L. Kong, D. Babu, R. Choudhary, W. Fam, J. Q. Tng, Y. Goh, B. Wong Jern Han, X. Liu, F. F. Song, P. Chia, M. C. Chan, O. An, C. Y. Tham, T. Benoukraf, , M. J. Fullwood

This study maps 3D genome organization in normal and AML haematopoietic stem cells, finding increased chromatin loops to oncogenes in AML and identifying MEIS1 and HOXA9 as key oncogenes regulated by these interactions.

bioRxiv · Apr 18, 2020 · PreprintCancer Biology

Multiple Myeloma: Combination Therapy of BET Proteolysis Targeting Chimeric Molecule with CDK9 Inhibitor

S. L. Lim, P. Koeffler, L. Xu, B. C. Han, P. Shyamsunder, W. J. Chng

This study shows that combining a BET PROTAC (ARV 825) with a CDK9 inhibitor (AZD 4573) effectively reduces multiple myeloma cell viability and induces apoptosis.

bioRxiv · Apr 8, 2020Cancer Biology